Maximus vs CoreAgeRx: Pricing, meds, and telemedicine compared
If you need a quick verdict: Maximus is a low flat-rate, telemedicine-first option for compounded semaglutide starting at $132.99/month, while CoreAgeRx emphasizes flat, unchanging monthly pricing and offers both semaglutide and tirzepatide price tiers.
Maximus vs CoreAgeRx differ most on price structure, medication types and dosing options, telemedicine workflow and pharmacy sourcing, and regulatory notes about compounded drugs. Early verdict: choose Maximus if you want a straightforward, low flat rate for compounded semaglutide from US pharmacies; choose CoreAgeRx if locking a flat monthly price and access to tirzepatide dosing options matter most.
Start Maximus semaglutide enrollment
How pricing and billing compare
Pricing is a primary distinction in the Maximus vs CoreAgeRx comparison. Maximus advertises a direct-pay model with a low flat rate highlighted as $132.99 per month for compounded semaglutide, with messaging that includes “starting at” pricing and references to $79.99/month in some captured content. CoreAgeRx positions itself around “Same Price. Every Month.” with explicit price points: semaglutide at $79 per month and tirzepatide at $129 per month, and an emphasis that prices do not increase over time and there are no membership fees.
Quick price takeaway
Maximus: direct-pay flat rate at $132.99/month for compounded semaglutide, no insurance billing. CoreAgeRx: fixed monthly prices with semaglutide at $79/month and tirzepatide at $129/month and an explicit claim of no price hikes.
See CoreAgeRx flat-price plans
Medication types, dosing, and availability
Direct comparison shows Maximus focuses on compounded semaglutide only and notes semaglutide 2.4mg messaging in marketing copy; Maximus explicitly states its medications are compounded in U.S. pharmacies. CoreAgeRx lists availability for both semaglutide and tirzepatide, with dosing claims of semaglutide up to 1.0 mg and tirzepatide up to 7.5 mg. CoreAgeRx also instructs that treatment is available only when a licensed clinician determines it is medically appropriate.
Telemedicine, clinician review, and pharmacy sourcing
Both providers use clinician review and telemedicine. Maximus markets convenient telemedicine access with prescriptions approved by licensed doctors and filled through trusted U.S. pharmacies, with no in-person clinic visits required. CoreAgeRx highlights a 3-minute online visit, no insurance required, and clinician review determining medical appropriateness. Maximus states it ships from U.S. pharmacies and lists state availability for one protocol as available in all 50 states except Mississippi. CoreAgeRx cautions that pricing, eligibility, pharmacy, state coverage and renewal terms may change and that medication-specific approval status must be confirmed.
Get Maximus telemedicine review
Regulatory and product notes to compare
Both sources include regulatory qualifiers about compounded medications. Maximus includes the clear statement that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. CoreAgeRx similarly notes that medication-specific approval status must be confirmed and that compounded medications, when offered, are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. CoreAgeRx also warns that branded and compounded products are not interchangeable. These qualifications affect how customers should interpret product claims.
Comparison table: Maximus vs CoreAgeRx
| Criteria | Maximus | CoreAgeRx |
|---|---|---|
| Starting price | Start with $132.99 Per Month (direct-pay) | Semaglutide $79/mo; Tirzepatide $129/mo; Same price every month |
| Medication types | Compounded semaglutide only (U.S. pharmacies) | Semaglutide up to 1.0 mg; Tirzepatide up to 7.5 mg |
| Telemedicine and clinician review | Convenient telemedicine; licensed doctors approve prescriptions | 3-minute online visit; licensed clinician determines appropriateness |
| Pharmacy sourcing | Compounded in U.S.-based pharmacies | Pharmacy and state coverage subject to live offer and may change |
| Regulatory note | Compounded meds not FDA-approved and not reviewed by FDA | Medication-specific approval must be confirmed; compounded meds not FDA-approved |
Customer experience and transparency differences
Maximus emphasizes a simple, no-frills direct-pay model with no insurance billing and a promise that if you are not approved your medication costs will be refunded. CoreAgeRx emphasizes predictable billing with no membership fees and warns customers that other programs may increase monthly costs; it also cautions that pricing and eligibility may change and advises confirming terms before enrollment.
Final comparison and recommendation
In sum, Maximus vs CoreAgeRx split along clear lines: Maximus is positioned as a lower-cost, telemedicine-first provider of compounded semaglutide dispensed from U.S. pharmacies with a flat advertised rate of $132.99/month and no insurance billing. CoreAgeRx stresses price stability and offers explicit monthly price points for semaglutide and tirzepatide and a claim of “Same Price. Every Month.” Regulatory cautions apply to compounded products from both providers.
Check CoreAgeRx pricing and eligibility
Compare Maximus details and begin
Choose Maximus if you want a straightforward, low flat rate for compounded semaglutide prescribed via telemedicine and filled through U.S. pharmacies. Choose CoreAgeRx if locking a flat monthly price and access to both semaglutide and tirzepatide dosing options are your priorities. For both, confirm clinician eligibility and note that compounded medications are not FDA-approved.